Cargando…
Strategies to Improve the Safety of iPSC-Derived β Cells for β Cell Replacement in Diabetes
Allogeneic islet transplantation allows for the re-establishment of glycemic control with the possibility of insulin independence, but is severely limited by the scarcity of organ donors. However, a new source of insulin-producing cells could enable the widespread use of cell therapy for diabetes tr...
Autores principales: | Pellegrini, Silvia, Zamarian, Valentina, Sordi, Valeria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448870/ https://www.ncbi.nlm.nih.gov/pubmed/36090777 http://dx.doi.org/10.3389/ti.2022.10575 |
Ejemplares similares
-
Treating iPSC-Derived β Cells with an Anti-CD30 Antibody–Drug Conjugate Eliminates the Risk of Teratoma Development upon Transplantation
por: Pellegrini, Silvia, et al.
Publicado: (2022) -
Differentiation of Sendai Virus-Reprogrammed iPSC into β Cells,
Compared with Human Pancreatic Islets and Immortalized β Cell
Line
por: Pellegrini, Silvia, et al.
Publicado: (2018) -
Engineering of immune checkpoints B7-H3 and CD155 enhances immune compatibility of MHC-I(−/−) iPSCs for β cell replacement
por: Chimienti, Raniero, et al.
Publicado: (2022) -
Clusterin Is Required for β-Amyloid Toxicity in Human iPSC-Derived Neurons
por: Robbins, Jacqueline P., et al.
Publicado: (2018) -
Probing the missing mature β-cell proteomic landscape in differentiating patient iPSC-derived cells
por: Vethe, Heidrun, et al.
Publicado: (2017)